Apollo Hospitals Enterprise Limited · NSE:APOLLOHOSP
Apollo Hospitals Enterprise — Q1 FY2022 Earnings Presentation
27 slides from Apollo Hospitals Enterprise's earnings presentation, Aug 14, 2021
Slide 1: Regulation 30 disclosure cover letter to stock exchanges
APOLLO HOSPITALS ENTERPRISE LIMITED A(bllo I HOSPITALS CIN: L85110TN1979PLC008035 TOUCHING LIVES 13th August 2021 The Secretary, The Secretary, The Manager Bombay Stock Exchange Ltd (BSE) National Stock Exchange, The National Stock Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor Exchange, Dal
Slide 2: Earnings Update Q1 FY 2022
EARNINGS UPDATE Q1 FY 2022 1
Slide 3: Disclaimer
DISCLAIMER • No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the
Slide 4: Key Highlights
Key Highlights HIGHLIGHTS STANDALONE FINANCIAL CONSOLIDATED FINANCIAL PERFORMANCE PERFORMANCE OPERATIONAL PARAMETERS - APOLLO 24/7 APOLLO HEALTH & LIFESTYLE HOSPITALS & PHARMACIES LTD 3
Slide 5: Highlights
HIGHLIGHTS i
Slide 6: Highlights
HIGHLIGHTS Q1 FY22 Consolidated Revenues of ` 37,602 mio (growth of 73% yoy). Q1 FY22 Consolidated EBITDA (Post Ind AS 116) of ` 5,199 mio. New Hospitals (excl Proton) reported an EBITDA of ` 1,024 mio in Q1 FY22 as compared to an EBITDA loss of ` (251) mio in Q1 FY21. Financial Proton repor
Slide 7: Highlights
HIGHLIGHTS 71 hospitals with total bed capacity of 10,209 beds as on June 30, 2021. 44 owned hospitals including JVs/ Subsidiaries and Associates with 8,816 beds. 11 Day care/ short surgical stay centres with 270 beds and 11 Cradles with 272 beds. Capacity 5 Managed hospitals with 851 beds.
Slide 8: COVID Testing and Treatment – Q1FY22
COVID TESTING AND TREATMENT – Q1FY22 ‘Project Stay I’ saw success with over 24,000 2,355 23,400 + room nights. Dedicated beds In -Patients Our effort in the Home care segment enabled 2,900+ us to move into 29,000 homes, (of which Stay I COVID care was at 20,000 homes) and provide medically super
Slide 9: Standalone Financial Performance
STANDALONE FINANCIAL PERFORMANCE
Slide 10: Standalone Financial Performance
STANDALONE FINANCIAL PERFORMANCE TOTAL (` mio) (` mio) Q1 FY 21 Q1 FY 22 yoy (%) Key Highlights Revenue 19,615 29,947 52.7% Operative Expenses 11,703 18,424 57.4% Q1 FY22 Revenues at ` 29,947 mio Employee Expenses 3,768 3,180 -15.6% Administrative & Other Expenses 3,730 4,437 18.9% Total Expenses 19
Slide 11: Standalone Financial Performance: Mature & New Breakup – Q1 FY22
STANDALONE FINANCIAL PERFORMANCE MATURE & NEW BREAKUP – Q1 FY22 (`(`mio) mio) Key Highlights Healthcare Healthcare Services New Services Pharmacy Standalone HCS revenue at ` 14,827 mio in Q1FY22 growth Distribution* of 117% (Mature) Hospitals Proton (Total) Hospitals 21 10 1 32 • Mature HCS revenue
Slide 12: Standalone Financial Performance: Segment Reporting
STANDALONE FINANCIAL PERFORMANCE SEGMENT REPORTING (` mio) Q1 FY 21 Q1 FY 22 yoy (%) Revenues from each segment Healthcare Services* 6,824 14,827 117.3% Stand-alone Pharmacy 12,791 Pharmacy Distribution** 0 15,120 Total 19,616 29,947 52.7% Less: Intersegmental Revenue 1 Net Revenues 19,615 29,947 52
Slide 13: Consolidated Financial Performance
CONSOLIDATED FINANCIAL PERFORMANCE
Slide 14: Consolidated Financial Performance
CONSOLIDATED FINANCIAL PERFORMANCE TOTAL (` mio) Q1 FY 21 Q1 FY 22 yoy (%) Key Highlights Total Revenues 21,715 37,602 73.2% EBITDA (Post Ind AS 116) 355 5,199 1365.3% Q1FY22 Consolidated Revenues at ` 37,602 mio margin (%) 1.6% 13.8% 1219 bps EBIT -1,247 3,793 -404.1% margin (%) -5.7% 10.1% 1583 bp
Slide 15: Consolidated Financial Performance: Mature & New Breakup – Q1 FY22
CONSOLIDATED FINANCIAL PERFORMANCE MATURE & NEW BREAKUP – Q1 FY22 (` mio) Healthcare Key Highlights Healthcare Healthcare Serv Serv Group Proton Serv Pharmacy AHLL Consol HCS revenue at ` 19,392 mio in Q1FY22, Group Group Distribution* (New & growth of 145% (Mature) (Total) Others) • Mature HCS reve
Slide 16: Operational Parameters - Hospitals & Pharmacies
OPERATIONAL PARAMETERS - HOSPITALS & PHARMACIES
Slide 17: Operational Parameters - Hospitals
OPERATIONAL PARAMETERS - HOSPITALS (` mio) Tamilnadu Region AP, Telengana Region Karnataka Region Significant Subs/JVs/associates Total (6) Others (4) (Chennai & others) (1) (Hyderabad & others) (2) (Bangalore & others) (3) (5) Particulars Q1 FY 21 Q1 FY 22 yoy (%) Q1 FY 21 Q1 FY 22 yoy (%) Q1 FY 21
Slide 18: Pharmacy Distribution
PHARMACY DISTRIBUTION (` mio) The Combined Pharmacy platform business reported Q1 FY 21 Q1 FY 22* yoy (%) revenue of ` 18,293 mio in Q1FY22 as compared to a Revenue of ` 12,791 mio in Q1FY21, 43% growth. Revenue 12,791 15,120 18.2% • The like-to-like EBITDA (Post Ind As 116) in Q1FY22 EBITDA (Post I
Slide 19: Apollo 24/7
APOLLO 24/7 i
Slide 20: Apollo 24x7 – India's Largest Omni-Channel Healthcare Platform
APOLLO 24X7 – INDIA’S LARGEST OMNI-CHANNEL HEALTHCARE PLATFORM LEVERAGING PHYSICAL NETWORK Distinctive digital 5 ecosystem … 4 Condition 6 management Digital services Online Health diagnostic predictor 3 booking 7 Well-being Part of Virtual doctor companion consultation Apollo 24/7 2 Online 8 Health
Slide 21: Distinctive digital ecosystem coupled with network and capabilities
Distinctive digital ecosystem… … coupled with adequate network and capabilities Cumulative upto 30th June 2021 Physical network & capabilities ~5.7 Lakh+ 1 2 3 Doctors across 3mm+ Annual Online Consults Diagnostic centers Hospitals & clinics chronic patients ~10 Mn completed 4 5 Registrations Levera
Slide 22: Apollo HealthCo
APOLLO HEALTHCO Awaiting Shareholders approval on 14th August for Reorganization through Slump Sale AHEL (Listed) • Apollo 24/7 represents Apollo Group’s transformational journey to creating “India’s Largest Omnichannel Digital Healthcare Platform” that: Backend combines the strengths of Apollo Gr
Slide 23: Apollo Health & Lifestyle Ltd
APOLLO HEALTH & LIFESTYLE LTD
Slide 24: AHLL – Q1 FY22
AHLL – Q1 FY22 (` mio) Clinics Diagnostics Sugar Dental Dialysis Cradles (IP) IVF Spectra (IP) Network 197 847 21 63 75 8 12 11 Footfalls/Day* 6796 13995 303 77 1096 38 14 53 Gross ARPP (Rs.)* 1567 610 2324 6690 1488 106474 35518 106912 Key Highlights AHLL reported EBITDA of ` 479 mio as compared to
Slide 25: Appendix 1: Ind AS 116 Impact on P&L and Balance Sheet
APPENDIX 1 : IND AS - 116 IMPACT ON P&L AND BALANCE SHEET – Q1FY22 (` mio) AHEL Standalone (post IND AS 116) AHEL Consolidated (post IND AS 116) Balance sheet Profit & Loss Balance sheet Profit & Loss Revenue - Right of use Revenue Right of use Asset as of 6,002 Asset as of 9,981 Other 211 Other exp
Slide 26: Appendix 2: Basis of Consolidation
APPENDIX 2 : BASIS OF CONSOLIDATION AHEL Standalone Location Description AHEL Ownership AHEL Chennai Main Chennai Hospital Subsidiaries Location Description Ownership ACI - Chennai Chennai Hospital Samudra Healthcare Enterprises Ltd. Kakinada Hospital 100.00% Tondiarpet - Chennai Chennai Hospital Ap
Slide 27: Thank You
THANK YOU 26
Apollo Hospitals Enterprise — Q1 FY2022 Earnings Presentation on 6ix